IDEXX Q1 2026: Beat-and-Raise as Diagnostics Growth Outpaces Slowing Vet Visits

Transcript intelligence

What changed

Revenue reached $1.14 billion, up 14% year-over-year (11% organic), beating the $1.12 billion consensus by approximately 2%. EPS of $3.47 exceeded the $3.41 estimate by 1.8%, growing 15% on a comparable basis. Management raised full-year guidance, a step up from the maintained posture in the prior quarter, where the initial 2026 outlook called for 7-9% revenue growth, 32-32.5% operating margin, and EPS of $14.29-$14.80. Premium instrument placements continued at a strong pace with 1,100 inVue Dx units in Q1, and international markets delivered double-digit growth with new Cancer DX launches in Europe and Australia. Two new headwinds not flagged in the prior quarter emerged: a $5 million loss on an equity investment that impacted Q1 earnings, and supply-chain disruptions in the Middle East affecting the Water business. The company also announced a leadership transition with Mike Erickson becoming CEO and Jay Mazelsky moving to Executive Chair.

Guidance delta

IDEXX raised its full-year fiscal 2026 outlook following the Q1 beat. The prior quarter (Q4 2025) guidance had projected 7-9% revenue growth, 32-32.5% operating margin, and EPS of $14.29-$14.80. The guidance sentiment shifted from maintained to raised, reflecting management's increased confidence after the strong first quarter. Specific updated numerical ranges were not detailed in the supplied transcript analysis, but the direction is clearly upward.

Key takeaways

• Q1 revenue rose 14% (11% organic) to $1.14 billion and EPS of $3.47 beat consensus by 1.8%, prompting raised full-year guidance.
• CAG Diagnostics recurring revenue ran 1,100 basis points ahead of declining U.S. clinical visits, demonstrating diagnostic intensity gains per visit.
• 1,100 inVue Dx placements in Q1 track toward a 5,500-unit annual target, extending the premium instrument installed base.
• International markets delivered double-digit growth, with Cancer DX launches in Europe and Australia expanding the global footprint.
• CEO transition announced: Mike Erickson to become CEO, Jay Mazelsky to Executive Chair.

Management priorities

• Achieve 5,500 total inVue Dx placements for 2026.
• Expand F&A rollout from controlled launch to unrestricted release later in the year.
• Grow Cancer DX menu with new tests, including mast cell tumor detection and a third test by end-2026.
• Scale DR50 PLUS imaging system deployments and continue cloud-native PIMS expansion.
• Release additional AI-driven software updates for inVue Dx and ezyVet platforms.